
United Therapeutics Corporation: shareholders and insiders
Price
$559.10
November 19, 2026Market cap $24.5B
What Ploutos Investor adds for United Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Vanguard Capital ManagementShare of class5.19%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Vanguard Capital Management | 5.19% | 2.28M | Apr 30, 2026 | 13G |
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter-1.9%
- Bridgewater (Dalio)In the quarter+13%
- Citadel Advisors (Griffin)In the quarter+205%
- Point72 (Cohen)In the quarter-12%
- Millennium Mgmt (Englander)In the quarter-27%
- AQR CapitalIn the quarter-22%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 1.68M | -1.9% | $908M | 1.24% |
| Bridgewater (Dalio) | 125.4K | +13% | $68M | 0.30% |
| Citadel Advisors (Griffin) | 928.5K | +205% | $503M | 0.28% |
| Point72 (Cohen) | 177.0K | -12% | $96M | 0.15% |
| Millennium Mgmt (Englander) | 297.4K | -27% | $161M | 0.12% |
| AQR Capital | 423.6K | -22% | $202M | 0.06% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short sales in daily trading
How much of the shares that changed hands were short sales, in the off-exchange trades brokers report each day.
In the last 14 sessions, 46.7% of the shares in the reported trades were short sales, against 65.4% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 46.7%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 65.4%
- Change
- -18.7 pts
- Short sales a dayon average, of 193.2K shares
- 90.1K
- More than atof 3,666 US-listed companies, same days
- 37%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 67.5%
- Oct 14, 2026: Short sales 60.7%
- Oct 15, 2026: Short sales 62.4%
- Oct 16, 2026: Short sales 69.6%
- Oct 19, 2026: Short sales 79.5%
- Oct 20, 2026: Short sales 74.1%
- Oct 21, 2026: Short sales 80%
- Oct 22, 2026: Short sales 73.9%
- Oct 23, 2026: Short sales 70%
- Oct 26, 2026: Short sales 59.1%
- Oct 27, 2026: Short sales 42.8%
- Oct 28, 2026: Short sales 47.4%
- Oct 29, 2026: Short sales 61.8%
- Oct 30, 2026: Short sales 68.2%
- Nov 2, 2026: Short sales 56.9%
- Nov 3, 2026: Short sales 35.6%
- Nov 4, 2026: Short sales 39.4%
- Nov 5, 2026: Short sales 42%
- Nov 6, 2026: Short sales 57.6%
- Nov 9, 2026: Short sales 54.2%
- Nov 10, 2026: Short sales 49.2%
- Nov 11, 2026: Short sales 58.1%
- Nov 12, 2026: Short sales 46.3%
- Nov 13, 2026: Short sales 44%
- Nov 16, 2026: Short sales 50.3%
- Nov 17, 2026: Short sales 44.2%
- Nov 18, 2026: Short sales 44.2%
- Nov 19, 2026: Short sales 44.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half. Shares held short, which are published twice a month, are not included here.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XMHQInvesco S&P MidCap Quality ETFWeight in the fund2.53%
- IBBiShares Biotechnology ETFWeight in the fund1.73%
- IJKiShares S&P Mid-Cap 400 Growth ETFWeight in the fund1.22%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.92%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.65%
- SPMDState Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETFWeight in the fund0.63%
- IJHiShares Core S&P Mid-Cap ETFWeight in the fund0.63%
- MDYState Street SPDR S&P MidCap 400SM ETF TrustWeight in the fund0.63%
- SCHMSchwab U.S. Mid-Cap ETFWeight in the fund0.40%
- IYHiShares U.S. Healthcare ETFWeight in the fund0.35%
49 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 710
- Q4 2025: Managers 837
- Q1 2026: Managers 857
- Q2 2026: Managers 880
Institutional investors by quarter
The fund managers holding UTHR, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 880 managers held 41.79M shares, worth $22.7B. During the quarter 106 opened a position, 83 closed one, 316 added and 326 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter-1.9%
- Avoro Capital AdvisorsIn the quarter+5.6%
- Vanguard Portfolio ManagementIn the quarter-4.2%
- Vanguard Capital ManagementIn the quarter-2.0%
- State StreetIn the quarter+2.9%
- Renaissance TechnologiesIn the quarter-4.4%
- Wellington Management GroupIn the quarter-39%
- Geode Capital ManagementIn the quarter-19%
- Jupiter TopcoIn the quarter
- Norges BankIn the quarter+15%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 5.29M | -1.9% | $2.9B |
| Avoro Capital Advisors | 2.78M | +5.6% | $1.5B |
| Vanguard Portfolio Management | 1.92M | -4.2% | $1.0B |
| Vanguard Capital Management | 1.92M | -2.0% | $1.0B |
| State Street | 1.90M | +2.9% | $1.0B |
| Renaissance Technologies | 1.71M | -4.4% | $926M |
| Wellington Management Group | 1.38M | -39% | $747M |
| Geode Capital Management | 996.6K | -19% | $539M |
| Jupiter Topco | 831.1K | $450M | |
| Norges Bank | 694.8K | +15% | $376M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do United Therapeutics's filings show?
Who buys and sells is one part of United Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which well-known managers hold UTHR?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $908M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.